External Use Authorized 605 15 July 2001 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme Clinuvel Pharmaceuticals Limited ACN/ARSN 089 644 119 1. Details of...
Ceasing to be a substantial holder
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
- CLINUVEL considers Nasdaq listing, ASX delisting
- Appendix 4E and Annual Report to Shareholders 2026
- A decade of profitability provides U.S. expansion foundation
- Investor Presentation
Later from Clinuvel Pharmaceuticals
- CLINUVEL develops proprietary ZEROKIN device
- CLINUVEL date of Annual General Meeting
- Becoming a substantial holder
- New CUV105 vitiligo cases presented to EADV
- Notice of Annual General Meeting/Proxy Form
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals